Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer

被引:32
作者
Bertolo, Cristina [1 ]
Guerrero, David [1 ]
Vicente, Francisco [2 ,4 ]
Cordoba, Alicia [3 ]
Esteller, Manel [5 ]
Ropero, Santiago [5 ]
Guillen-Grima, Francisco [6 ,7 ]
Maria Martinez-Penuela, Jose [3 ]
Miguel Lera, Jose [2 ]
机构
[1] Navarra Hlth Serv, Biomed Res Ctr, Pamplona, Spain
[2] Navarra Hlth Serv, Dept Surg, Pamplona, Spain
[3] Navarra Hlth Serv, Dept Pathol, Pamplona, Spain
[4] Univ Navarra, Dept Nursing Care Adult Person, E-31080 Pamplona, Spain
[5] Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Madrid, Spain
[6] Univ Navarra Clin, Dept Prevent Med, Pamplona, Spain
[7] Univ Publ Navarra, Dept Hlth Sci, Pamplona, Spain
关键词
breast cancer subtypes; hypermethylation; prognosis; tissue microarray; tumor markers;
D O I
10.1309/J3QV9763DYPV338D
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Breast cancer is a heterogeneous disease, and patients are categorized into subtypes according to gene expression. We studied the associations among molecular, immunohistochemical, and clinicopathologic features and their distribution according to the subtypes luminal. HER2, basal, and normal-like in 60 patients with invasive ductal breast carcinoma without distant metastasis at the time of diagnosis (M0). We evaluated the hypermethylation of the CDH-1, RASSF1A, SIAH-1 and TSLC-1 genes by methylation-specific polymerase chain reaction and the expression of p53, bcl-2, cyclin D1, E-cadherin, and beta-catenin proteins in tissue microarrays by immunohistochemical analysis. Expression of bcl-2 was associated with the luminal subtypes (P = .003), and CDH-1 hypermethylation was present perferentially in Her2 tumors (P = .038). The basal subtype was characterized by the expression of beta-catenin (P = .003). The hypermethylation of CDH-1 and the expression of bcl-2, cyclin D1, and beta-catenin proteins differ among breast cancer subtypes.
引用
收藏
页码:414 / 424
页数:11
相关论文
共 65 条
[1]   Role of the ras-association domain family 1 tumor suppressor gene in human cancers [J].
Agathanggelou, A ;
Cooper, WN ;
Latif, F .
CANCER RESEARCH, 2005, 65 (09) :3497-3508
[2]   Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer:: Indications of TSLC1 promoter hypermethylation [J].
Allinen, M ;
Peri, L ;
Kujala, S ;
Lahti-Domenici, J ;
Outila, K ;
Karppinen, SM ;
Launonen, V ;
Winqvist, R .
GENES CHROMOSOMES & CANCER, 2002, 34 (04) :384-389
[3]   Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers [J].
Arai, Takashi ;
Miyoshi, Yasuo ;
Kim, Seung Jin ;
Taguchi, Tetsuya ;
Tamaki, Yasuhiro ;
Noguchi, Shinzaburo .
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (02) :169-176
[4]   Cyclin D1 in breast cancer pathogenesis [J].
Arnold, A ;
Papanikolaou, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4215-4224
[5]  
Bànkfalvi A, 1999, HISTOPATHOLOGY, V34, P25
[6]   Breast cancer incidence and mortality trends in 16 European countries [J].
Botha, JL ;
Bray, F ;
Sankila, R ;
Parkin, DM .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (12) :1718-1729
[7]   Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? [J].
Brenton, JD ;
Carey, LA ;
Ahmed, AA ;
Caldas, C .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (29) :7350-7360
[8]   CDHI promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer [J].
Caldeira, Jose Roberto F. ;
Prando, Erika C. ;
Quevedo, Francisco C. ;
Moraes Neto, Francisco A. ;
Rainho, Claudia A. ;
Rogatto, Silvia R. .
BMC CANCER, 2006, 6 (1)
[9]   Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index [J].
Callagy, GM ;
Pharoah, PD ;
Pinder, SE ;
Hsu, FD ;
Nielsen, TO ;
Ragaz, J ;
Ellis, IO ;
Huntsman, D ;
Caldas, C .
CLINICAL CANCER RESEARCH, 2006, 12 (08) :2468-2475
[10]   The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].
Carey, Lisa A. ;
Dees, E. Claire ;
Sawyer, Lynda ;
Gatti, Lisa ;
Moore, Dominic T. ;
Collichio, Frances ;
Ollila, David W. ;
Sartor, Carolyn I. ;
Graham, Mark L. ;
Perou, Charles M. .
CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334